Admin-Core-001

管理核心-001

基本信息

批准号：
10709110
负责人：
Scott Dexter Boyd
金额：
$ 44万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10709110
关键词：
2019-nCoV Acute Address African American population Agonist Antibodies Antigen Targeting Attention Award B-Lymphocytes Biopsy Blood COVID-19 COVID-19 diagnosis COVID-19 patient COVID-19 test Cancer Patient Caucasians Cells Clinical Collaborations Communities Convalescence Data Data Set Disease Elderly Evaluation Female Hispanic Americans Human Immune Immune response Immune system Immunity Immunologic Memory Immunologics Individual Infection Institution Knowledge Laboratories Longitudinal Studies Mucosal Immune Responses Mucous Membrane Nose Patient Recruitments Patients Peripheral Blood Mononuclear Cell Phenotype Physicians Plasma Plasma Cells Populations at Risk Prognosis Protocols documentation Research Risk Route SARS-CoV-2 immune response SARS-CoV-2 immunity SARS-CoV-2 infection Science Serology Severity of illness Site T cell response T-Lymphocyte Testing Tissue Sample Toll-like receptors Translational Research Translations Vaccination Validation Viral Antigens adaptive immune response adaptive immunity base clinical development cohort data sharing immune checkpoint blockade interest male medically underserved medically underserved population member mucosal site novel therapeutic intervention pandemic coronavirus pandemic disease patient population research clinical testing response tool vaccine candidate vaccine trial young adult

项目摘要

OVERALL: SUMMARY We propose the Stanford U54 SARS-CoV-2 Serological Sciences Center of Excellence (SUSS-COE) as a member of the SeroNet consortium gathered to address the urgent need for better understanding of human immune responses to the SARS-CoV-2 coronavirus pandemic that has engulfed the U.S. and the world. Our Center will be based on four scientific pillars:  Deep mechanistic analysis of the adaptive immune responses of COVID-19 patients, spanning serological, B cell and T cell responses,  Analysis of immune responses in the blood as well as mucosal sites,  Comparing immune responses induced by infection to those induced by candidate vaccines, and  Studying medically underserved, underrepresented and at-risk patient populations Within these parameters, we will attempt to determine the factors that result in effective and durable immunity to SARS-CoV-2 infection. We are dedicated to broad collaboration, rapid sharing of data and technical knowledge, nimbleness in responding to the rapidly changing pandemic, and rapid translation of research findings to CLIA Lab clinical testing and development of new therapeutic approaches. We feel these are the best routes forward for addressing gaps in our understanding of the determinants of protective immunity to SARS-CoV-2, and providing useful tools for physicians and patients.

总体：摘要我们提出了斯坦福U54 SARS-COV-2血清学科学卓越中心（SUSS-COE）聚集的Seronet财团成员是为了满足对人类更好理解的迫切需求免疫对吞噬美国和世界的SARS-COV-2冠状病毒大流行的反应。我们的中心将基于四个科学支柱： 跨越19例患者的自适应免疫复杂的深度机械分析血清学，B细胞和T细胞反应， 分析血液中的免疫回应以及粘膜部位， 将感染诱导的免疫调查与候选疫苗诱导的免疫调查和 研究医疗服务不足，代表性不足和处于危险的患者人群在这些参数中，我们将尝试确定导致有效耐用免疫力的因素致SARS-COV-2感染。我们致力于广泛的合作，数据和技术知识的快速共享，敏捷性响应迅速变化的大流行，并将研究结果迅速转化为Clia Lab临床测试和开发新的治疗方法。我们认为这些是前进的最佳路线解决我们对SARS-COV-2保护性豁免权的决定者的理解中的差距，以及为医师和患者提供有用的工具。